1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders 3rd edition. Cephalalgia 2018; 38(1): 1–211.
Google Scholar | SAGE Journals2. Natoli, JL, Manack, A, Dean, B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010; 30(5): 599–609.
Google Scholar | SAGE Journals | ISI3. Lanteri-Minet, M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep 2014; 18(1): 385.
Google Scholar | Crossref | Medline4. Leonardi, M, Raggi, A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain 2019; 20(1): 41.
Google Scholar | Crossref | Medline5. British Association for the Study of Headache Guideline Group . National Headache Management System for Adults 2019, http://headache.org.uk/index.php/bash-guideline-2019 (accessed 15 August 2020).
Google Scholar6. Diamond, S, Bigal, ME, Silberstein, S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American migraine prevalence and prevention study. Headache 2007; 47(3): 355–363.
Google Scholar | Medline | ISI7. Hepp, Z, Dodick, DW, Varon, SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 2017; 37(5): 470–485.
Google Scholar | SAGE Journals | ISI8. Huang, W, Foster, JA, Rogachefsky, AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000; 43(2Pt1): 249–259.
Google Scholar | Crossref | Medline9. Ward, AB, Molenaers, G, Colosimo, C, et al. Clinical value of botulinum toxin in neurological indications. Eur J Neurol 2006; 13(Suppl. 4): 20–26.
Google Scholar | Crossref | Medline10. Brin, MF, Fahn, S, Moskowitz, C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987; 2(4): 237–254.
Google Scholar | Crossref | Medline11. Aoki, KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26(5): 785–793.
Google Scholar | Crossref | Medline12. Dolly, JO, O’Connell, MA. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol 2012; 12(1): 100–108.
Google Scholar | Crossref | Medline13. Binder, WJ, Blitzer, A, Brin, MF. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol Surg 1998; 24(11): 1198–1205.
Google Scholar | Crossref | Medline14. Binder, WJ, Brin, MF, Blitzer, A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000; 123(6): 669–676.
Google Scholar | SAGE Journals | ISI15. Blumenfeld, AM, Binder, W, Silberstein, SD, et al. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003; 43(8): 884–891.
Google Scholar | Crossref | Medline16. Silberstein, SD, Stark, SR, Lucas, SM, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80(9): 1126–1137.
Google Scholar | Crossref | Medline17. Mathew, NT, Frishberg, BM, Gawel, M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45(4): 293–307.
Google Scholar | Crossref | Medline18. Aurora, SK, Gawel, M, Brandes, JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007; 47(4): 486–499.
Google Scholar | Medline19. Aurora, SK, Dodick, DW, Turkel, CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30(7): 793–803.
Google Scholar | SAGE Journals | ISI20. Diener, HC, Dodick, DW, Aurora, SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30(7): 804–814.
Google Scholar | SAGE Journals | ISI21. Dodick, DW, Turkel, CC, DeGryse, RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50(6): 921–936.
Google Scholar | Crossref | Medline22. Kudrow, L. Paradoxical effects of frequent analgesic use. Adv Neurol 1982; 33: 335–341.
Google Scholar | Medline23. Zeeberg, P, Olesen, J, Jensen, R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006; 26(10): 1192–1198.
Google Scholar | SAGE Journals | ISI24. Lipton, RB, Goadsby, PJ, Cady, RK, et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine [abstract PO47]. Cephalalgia 2009; 29: 30.
Google Scholar | ISI25. Diener, HC, Dodick, DW, Goadsby, PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009; 29(10): 1021–1027.
Google Scholar | SAGE Journals | ISI26. Linde, M, Mulleners, WM, Chronicle, EP, et al. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; 2013(6): Cd010610.
Google Scholar27. Pijpers, JA, Kies, DA, Louter, MA, et al. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain 2019; 142(5): 1203–1214.
Google Scholar | Crossref | Medline28. Blumenfeld, AM, Stark, RJ, Freeman, MC, et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018; 19(1): 13.
Google Scholar | Crossref | Medline29. Young, WB, Ivan Lopez, J, Rothrock, JF, et al. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. J Headache Pain 2019; 20(1): 12.
Google Scholar | Crossref | Medline30. Rendas-Baum, R, Yang, M, Varon, SF, et al. Validation of the headache impact test (HIT-6) in patients with chronic migraine. Health Qual Life Outcomes 2014; 12: 117.
Google Scholar | Crossref | Medline | ISI31. Wang, M, Cittadini, E, Bahra, A. EHMTC-0056: New Daily Persistent Headache: A clinical study with diagnostic implications. Cephalalgia 2016; 36(1_Suppl): 132.
Google Scholar32. Tassorelli, C, Diener, HC, Dodick, DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 2018; 38(5): 815–832.
Google Scholar | SAGE Journals | ISI33. Bjorner, JB, Kosinski, M, Ware, JE Using item response theory to calibrate the headache impact test (HIT) to the metric of traditional headache scales. Qual Life Res 2003; 12(8): 981–1002.
Google Scholar | Crossref | Medline34. Yang, M, Rendas-Baum, R, Varon, SF, et al. Validation of the headache impact test (HIT-6) across episodic and chronic migraine. Cephalalgia 2011; 31(3): 357–367.
Google Scholar | SAGE Journals | ISI